Zydus Lifesciences gets USFDA EIR for API Ahmedabad facility
Ahmedabad: Zydus Lifesciences has announced that the Company has received the EIR report from the United States Food and Drug Administration (USFDA) for the inspection
conducted at the API Ahmedabad facility.
The company had earlier received Post Application Action
Letter from the USFDA for the same inspection confirming that the inspected facility has been
considered as ready to commercially manufacture and supply the API.
Read also: USFDA gives nod for commercial production at Zydus Ahmedabad API unit
“This facility underwent an
inspection from 14th to 22nd Dec 2023 and has been classified as Voluntary Action Indicated (VAI),” the Company stated in a BSE filing.
Formerly known as Cadila Healthcare Limited, Zydus Lifesciences Limited is an Indian multinational pharmaceutical company headquartered in Ahmedabad. The company is primarily engaged in the production of generic drugs. Cadila was founded in 1952 by Ramanbhai Patel.
Read also: Zydus Lifesciences aims to launch first new drug in US by early 2026
